Conference Reports for NATAP

The 21st Conference of the Asian Pacific Association for the Study of the Liver APASL Feb 17-20, 2011 Bangkok, Thailand Back

Can HCV Be Cured Without Peg/RBV: Combination BMS-790052, BMS-650032 and pegIFN/RBV Provides Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders       Reported by Jules Levin   21st APASL Conference, Bangkok, Thailand, February 17-20, 2011   This study was presented at AASLD Nov 2010.   Gardiner DF,1 Lok A,2 Lawitz E,3 Martorell C,4 Everson G,5 Ghalib R,6 Reindollar R,7 Rustgi V,8 Wendelburg P,1 Zhu K,1 Shah V,1 Sherman D,1 McPhee F,9 Wind-Rotolo M,10 Bifano M,1 Eley T,1 Guo T,9 Persson A,10 Hindes R,9 Grasela D,1 and Pasquinelli C1 1Bristol-Myers Squibb, Research and Development, Hopewell, NJ, USA; 2University of Michigan, Ann Arbor, MI, USA; 3Alamo Medical Research, San Antonio, TX, USA; 4The Research Institute, Springfield, MA, USA; 5University of Colorado-Denver, Aurora, CO, USA; 6North Texas Research Institute, Arlington, TX, USA; 7Carolinas Center for Liver Disease, Statesville, NC, USA; 8Metropolitan Research, Fairfax, VA, USA; 9Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA; 10Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA   BACKGROUND   ·BMS-790052 is a first-in-class, highly selective HCV NS5A Replication Complex Inhibitor (RCI) with picomolar in vitro potency   ·BMS-650032 is a highly active HCV NS3 protease inhibitor   ·Both BMS-790052 and BMS-650032 have been shown to be generally well-tolerated and to produce robust declines in HCV RNA levels following multiple dosing in subjects chronically infected with HCV genotype 1   ·The coadministration of BMS-790052 and BMS-650032 did not result in a clinically meaningful pharmacokinetic interaction in healthy volunteers   ·HCV patients who are null responders to pegylated interferon and ribavirin (pegIFN/RBV) may benefit from combination therapy including 2